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ABSTRACT: Congenital disorder of glycosylation type
Ia (PMM2-CDG), the most common form of CDG, is
caused by mutations in the PMM2 gene that reduce phos-
phomannomutase 2 (PMM2) activity. No curative treat-
ment is available. The present work describes the func-
tional analysis of nine human PMM2 mutant proteins
frequently found in PMM2-CDG patients and also two
murine Pmm2 mutations carried by the unique PMM2-
CDG mouse model described to overcome embryonic
lethality. The effects of the mutations on PMM2/Pmm2
stability, oligomerization, and enzyme activity were ex-
plored in an optimized bacterial system. The mutant pro-
teins were associated with an enzymatic activity of up
to 47.3% as compared with wild type (WT). Stability
analysis performed using differential scanning fluorimetry
and a bacterial transcription–translation-coupled system
allowed the identification of several destabilizing muta-
tions (p.V44A, p.D65Y, p.R123Q, p.R141H, p.R162W,
p.F207S, p.T237M, p.C241S). Exclusion chromatog-
raphy identified one mutation, p.P113L, that affected
dimer interaction. Expression analysis of the p.V44A,
p.D65Y, p.R162W, and p.T237M mutations in a eukary-
otic expression system under permissive folding condi-
tions showed the possibility of recovering their associated
PMM2 activity. Together, the results suggest that some
loss-of-function mutations detected in PMM2-CDG pa-
tients could be destabilizing, and therefore PMM2 activity
could be, in certain cases, rescuable via the use of syner-
getic proteostasis modulators and/or chaperones.
Hum Mutat 36:851–860, 2015. C© 2015 Wiley Periodicals, Inc.
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Introduction
Over 70 diseases have been identified as congenital disorders of
glycosylation (CDG) [Hennet, 2012; Foulquier et al., 2012; Freeze
et al., 2014]-inherited metabolic disorders caused by defects in the
biosynthesis of glycoconjugates. The vast majority involve protein
hypoglycosylation defects, but in recent years, several defects of lipid
glycosylation have also been identified [Jaeken and Matthijs, 2007;
Freeze et al., 2014]. Defects in the N-glycosylation pathway account
for most protein glycosylation disorders; the remainder involve the
O-glycosylation pathway or both N- and O-glycosylation together.
No C-glycosylation defects are known.
Congenital disorder of glycosylation type Ia (PMM2-CDG;MIM
#212065) is caused bymutations in the PMM2 gene (MIM#601785)
[Matthijs et al., 1997] that reduce the activity of their product
enzyme phosphomannomutase 2 (PMM2) [Van Schaftingen and
Jaeken, 1995]. No strong genotype–phenotype correlation exists
[Grunewald et al., 2001] that might suggest the involvement of any
other gene, and as it has been suggested for anALG6 polymorphism,
it is twice as common in severely affected PMM2-CDG patients
than in patients classified as moderate/mild [Westphal et al., 2002].
PMM2, a homodimeric cytosolic protein, plays an important role in
N-glycosylation by competing with phosphomannose isomerase for
mannose-6-phosphate, converting it intomannose-1-phosphate for
entry into the N-glycosylation pathway. Over 1,000 cases of PMM2-
CDG [Cylwik et al., 2013] have been reported, involving 116 mu-
tations, most of them (83.6%) missense changes (HGMD
R©
pro-
fessional release 2014.3, http://www.hgmd.cf.ac.uk/ac/index.php)
[Stenson et al., 2014].Patients with this type of changes are usu-
ally compound heterozygous for two different missense mutations.
One severemutation, p.R141H, is particularly common in every an-
alyzed cohort of patients, but in spite of the high number of detected
carriers, no homozygous patients have been reported [Briones et al.,
2002; Kjaergaard et al., 1998; Le Bizec et al., 2005; Matthijs et al.,
1998].
The hypoglycosylation of glycoproteins and other glycoconju-
gates affects the functioning of multiple body systems. Currently,
there is no curative treatment for patients with PMM2-CDG; most
of those affected suffer motor problems and mental retardation
[Freeze, 2006], and their prognosis can be extremely poor. How-
ever, patients with very mild disease have been reported [Giurgea
et al., 2005], some of whom show under 25% of normal enzyme ac-
tivity. Indeed, their heterozygous parents, with 50% activity, remain
asymptomatic [Freeze, 2009]. Such a high symptomatic threshold
suggests that increasing the PMM2 activity of patients with PMM2-
CDGmight be very beneficial. Certainly, it has beenwidely observed
C© 2015 WILEY PERIODICALS, INC.
that patients with high residual activity tend to have milder pheno-
types [Westphal et al., 2002].
Some therapeutic approaches for PMM2-CDG have been pro-
posed.MPI enzyme inhibition combinedwithmannose administra-
tion or bypassing the defect by membrane permeable mannose-1-P
have been suggested [Freeze, 2009]. However, sugar supplementa-
tion presents some important hurdles such as the fact that mannose
metabolic flux should be manipulated cautiously [Cline et al., 2012;
Sharma et al., 2014a; Sharma et al., 2014b] and the need to study and
develop a delivery system to the cell for mannose-1-phosphate [Ek-
lund et al., 2005; Freeze, 2009; Hardre et al., 2007]. Other proposed
therapies could be enzyme replacement or gene therapy, although
the main problem would be the intracellular loading or the research
on gene delivery safety. Over the last decade, pharmacological chap-
erones have emerged as a novel therapeutic tool to rescue misfolded
proteins by stimulating and preserving their correct folding [Mar-
tinez et al., 2008; Muntau et al., 2014].
The aimof the presentworkwas to search for candidatemutations
thatmight be rescued by such treatment. ThePMM2protein expres-
sion system was therefore optimized in a bacterial system, allowing
a number of human PMM2mutant proteins detected among Span-
ish PMM2-CDG patients [Perez et al., 2011]—p.V44A (c.131T>C),
p.D65Y (c.193G>T), p.P113L (c.338C>T), p.R123Q (c.368G>A),
p.R141H (c.422G>A), p.R162W (c.484C>T), p.F207S (c.620T>C),
p.T237M (c.710C>T), and p.C241S (c.722G>C)—to be purified in
their native states. The stability and activity of someof these proteins
were then examined in a eukaryotic system.
Two murine Pmm2 mutant proteins, p.F118L (c.354C>G) and
p.R137H (c.310 311delinsAC.; analogous to the p.R141Hmutant in
humans), were also expressed in a bacterial system to investigate the
molecular mechanism underlying the benefit of prenatal mannose
supplementation in dams at risk of having pups carrying these two
mutations [Schneider et al., 2012]. The study of these twomutations
would allow to test the feasibility of the PMM2-CDGmurinemodel
as a mean of investigating proteostasis and chaperone therapies’
strategies.
Together, the results suggest that loss-of-function mutations are
destabilizing, but that PMM2 activity may sometimes be rescuable.
Materials and Methods
Wild-Type PMM2 and Mutant Gene Expression
The expression plasmid pDEST17-18 encoding human PMM2
(NM 000303.2) plus an N-terminal His6-tag, and pReceiver-B01
encoding mouse Pmm2 (NM 016881.2) plus an N-terminal His6-
tag (Source BioScience), were used to transform E. coli strain
BL21StarTMDE3 One Shot Cells (Invitrogen, Carlsbad, CA, USA).
PMM2mutations were introduced by site-directed mutagenesis us-
ing the QuikChange Mutagenesis Kit (Stratagene, Cedar Drive, TX,
USA) and specially designed primers. All products were verified
by DNA sequencing. Mutation nomenclature is based on cDNA
sequence (PMM2 NM 000303.2; Pmm2 NM 016881.2) using +1
as the A of the ATG translation initiation codon in the reference
sequence, considering the initiation codon as codon 1. For protein
expression, bacteria were grown inmodified TYMmedium (Studier
autoinductionmedium [Studier, 2005] withN–Z amine replaced by
tryptone) containing25μg/ml zeocineovernight at 37°C.Cellswere
harvested by centrifugation, resuspended in 20mMHEPES, 25mM
KCl, 1 mM DTT, pH 7, and 1× Complete Mini, EDTA-free Pro-
tease Inhibitor Cocktail (Roche Applied Biosciences, Indianapolis,
IN, USA), lysed by sonication, and then centrifuged at 4°C. Protein
concentrations were determined following the Bradford method
[Bradford, 1976] using Bio-Rad Protein Assay Reagent (Bio-Rad,
Munchen, Germany). This crude soluble cell extract was used for
protein activity assays, western blotting, and protein purification.
Protein Purification
Proteinpurificationwasperformedusing the A¨KTAPrimeSystem
(GE healthcare, Buckinghamshire, UK) at 4°C. The crude extract
was loaded onto a HisTrap
TM
High Performance affinity column
(GE Healthcare) equilibrated with 10 mM imidazole, 0.5 M NaCl,
20 mM sodium phosphate, pH 7.4, and eluted with an imidazole
gradient from 10 mM to 1 M. The eluted protein fractions were
pooled and loaded into a Superdex 200 HiLoad 16/60 size exclusion
chromatography column (GE healthcare). The elution fraction cor-
responding to dimeric PMM2 was recovered and stored for further
experiments. The pure protein concentrationwas estimated bymea-
suring the absorbance at 280 nm in a Nanodrop spectrophotometer
(ThermoScientific,Waltham,MA,USA)using the theoreticalmolar
extinction coefficient estimated from the amino acid composition
of HisPMM2 (23,755 M–1/cm).
Western Blotting
Samples were subjected to electrophoresis in 10%NuPAGE
R©
Bis-
Tris Precast Gels (Invitrogen). ProSieve
R©
Color Protein Markers
(Lonza, Basel, Switzerland) were used as molecular weight markers.
Proteins were transferred to a nitrocellulose membrane using the
iBlot
R©
Dry Blotting System (Invitrogen). Membranes were blocked
for at least 1 hr with 0.05% PBS-Tween and 5% low-fat milk. Im-
munodetection was performed using primary mouse polyclonal
antibodies to PMM2 protein (A01; Abnova, Heidelberg, Germany),
polyhistidine Sigma-Aldrich (St. Louis, MO, USA) and tubulin
(Sigma-Aldrich). Conjugated goat antimouse immunoglobulin G
horseradish peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) was used as the secondary antibody. The Enhanced Chemi-
luminescence System (GE healthcare) was used as the detection
method. Relative amounts of protein were determined by densit-
ometry using a Bio-Rad GS710 Calibrated Imaging Densitometer
running Quantity One 4.3.1 software (Bio-Rad).
Cell Culture
Patient-derived fibroblasts (P1–P4) were grown frompatient skin
biopsies (taken with informed consent) following standard condi-
tions in minimal essential medium supplemented with 1% glu-
tamine, 10 % fetal calf serum, and antibiotics. These cells were then
immortalized using pBABE-puro containing SV40 DNA sequences
(courtesyofDr. J.A. Enrı´quez). TheGM08680 cell line (Coriell Insti-
tute for Medical Research, NIGMSHuman Genetic Cell Repository,
Camden, New Jersey) was used as a control.
PMM2 Activity Assay
The PMM2 activity of the bacterial extract and pure protein
was assayed using the method of Van Schaftingen and Jaeken
[Van Schaftingen and Jaeken, 1995], as modified by de Koning et al.
[1998], but doubling the reagent concentrations. Assays were per-
formed using 50 ng of nanodrop-measured pure dimeric protein,
or 300 ng of bacterial extract as measured by the Bio-Rad Protein
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Assay (Bio-Rad). The reaction is measured by NADPH presence at
340 nm.
To improve the reproducibility and sensitivity of the results for
PMM2 activity in patient-derived fibroblasts, changes were intro-
duced to the classic activity assay, the lysis buffer, in order to obtain
higher amount of protein from less amount of cells, and the way
in which the product signal was measured, using a fluorimetric kit
and finally measuring the NADPH production by fluorescence at
540/590 nm. These modifications increased the reproducibility and
sensitivity of thewholemethod and allowed theuse of 96-well plates,
rendering the process more suited to high-throughput evaluation.
Some 15,000 cells per well were seeded in a 96-well plate and
lysed using Complete Lysis M reagent (Roche Applied Biosciences).
PMM2 activity was assayed using the same method as for the bac-
terial extracts and pure protein, incubating the plates for 45 min, or
4 hr for the P3 and P4 cell line. The NADPH production signal was
increased using the Amplite Fluorimetric NADPH assay Kit (AAT
Bioquest, Sunnyvale, CA, USA). Protein extracts from fibroblasts
were measured using the Bio-Rad Protein Assay (Bio-Rad).
Differential Scanning Fluorimetry
The stability of purified PMM2 was assessed by differential scan-
ning fluorimetry (DSF) [Niesen et al., 2007], monitoring its ther-
mal denaturation in the presence of the extrinsic fluorescent probe
SYPRO Orange (Sigma–Aldrich). Final volumes of 50 μl contain-
ing 0.075 mg/ml of pure PMM2 in 20 mM Na-HEPES pH 7.0, 200
mM NaCl, and 5x SYPRO Orange were dispensed into LightCy-
cler480 Multiwell 96-well PCR-plates (Roche Applied Biosciences).
These were then loaded into a Light Cycler 480 (Roche Applied Bio-
sciences) for thermal denaturation. Unfolding curves were recorded
from 20°C to 85°C at a scan rate of 2°C/min. The increase in SYPRO
Orange fluorescence intensity associated with protein unfolding
(λexcitation = 465 nm; λemission = 580 nm) was monitored as a measure
of thermal denaturation. The experimental unfolding curves were
then smoothed, normalized, and analyzed using in-house software,
fitting the data to sigmoid curves using an asymmetry parameter
[Pey et al., 2008]. The midpoint melting temperature (Tm) was cal-
culated as that at which half of the protein was in the unfolded
state.
Thermal Stability Profiles
Dimeric PMM2 used for thermal stability analysis was pro-
duced by the RTS 100 E.coli HY kit (5 PRIME, Hilden, Germany)
transcription–translation-coupled system, following the manufac-
turer’s recommendations. After 30 min of incubation at 30°C to
produce human PMM2, or 60 min to generate mouse Pmm2, the
reactionwas stopped by adding 1μl of DNase andRNase (1mg/ml).
The whole reaction was incubated at 37°C, and 1.5 μl aliquots re-
moved at different times. Samples were examined by western blot-
ting as described above.
FoldX Prediction
FoldX is a computer algorithm that provides a quantitative es-
timate of the importance of the interactions contributing to the
stability of proteins and protein complexes. It uses a full atomic
description of the structure of proteins. The different energy terms
taken into account were weighted using empirical data obtained
from protein-engineering experiments. For a detailed explanation
of the FoldX force field, see Schymkowitz et al. [2005a, 2005b] and
information on the FoldX Web server (http://foldx.crg.es).
To study the effects of PMM2 mutations on protein stability,
the <BuildModel> command in FoldX v.3.0 and the PMM2 PDB
file 2AMY (PMM2 monomer), previously programmed using the
RepairPDB command, was used. The effect of the mutation was
computed by subtracting the energy of the WT from that of the
mutant (positive numbers mean less stability). The difference in
energy between the mutation and the WT reference is provided in
kilocalories per mole.
Lentiviral Constructs
The full-length ORF of human PMM2 was cloned into the mam-
malian lentiviral plasmid pReceiver-Lv101 (EX-M0134-Lv101),
which contains the FLAG tag preceding the multiple cloning site
(GeneCopoeia, Rockville, MD). Lentiviral stock production and fi-
broblast infection were performed as described elsewhere [Richard
et al., 2013]. Efficiently infected fibroblasts were selected by Ge-
neticin treatment.
Statistical Analysis
Statistical analyses were performed using IBM SPSS Statistics 21
software for Windows. One-way ANOVA followed by a Bonferroni
post hoc test was used to compare PMM2 activity and stability as
measured by DSF and the degradation time course assays.
Results
Human His6-PMM2 WT and p.V44A, p.D65Y, p.P113L,
p.R123Q, p.R141H, p.R162W, p.F207S, p.T237M, and p.C241S,
and mouse His6-Pmm2WT, p.F118L and p.R137H, were expressed
in the above-mentioned prokaryotic system. Western blotting
performed with the soluble protein extracts showed the amount of
PMM2 to be reduced for all mutants compared withWT, except for
the mouse p.F118L mutant. No soluble protein was detected for the
p.F207S mutant (Supp. Fig. S1). Using this well-established system,
we have studied the effect of thesemutations on the oligomerization
profile, activity, and stability of the PMM2 protein.
Oligomerization Profiles
The different oligomeric states of the mutant proteins were ana-
lyzed by size-exclusion chromatography. His6PMM2 WT and mu-
tantswere purifiedby affinity chromatography and then loadedonto
a size-exclusion chromatography column to obtain an oligomeriza-
tion profile. For all human PMM2 mutants, the amount of pure
protein obtained after purification was <30% that obtained with the
WT (starting with the same amount of bacterial culture) (Table 1].
Exclusion chromatography analysis revealed three oligomerization
patterns: (1) the mutants p.V44A, p.D65Y, p.R162W, and p.T237M
showed oligomeric profiles similar to that of the WT, with abun-
dance of the dimeric fraction; (2) p.R123Q, p.R141H and p.C241S
showed profiles with a predominant aggregate fraction; and (3)
mutant p.P113L returned no oligomeric profile (Fig. 1A and C;
Table 1). Mutation p.P113L acts at the interface between the dimer
subunits and probably affects dimerization [Silvaggi et al., 2006;
Vega et al., 2011]. No p.F207S protein could be purified given the
lack of soluble protein expression in the prokaryotic system (Supp.
Fig. S1).
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Figure 1. PMM2mutant oligomerization patterns.A: Size-exclusion chromatograms for the humanmutant PMM2 proteins. The gray arrow points
to the aggregate peak and the black arrow to the His6PMM2 dimer peak. B: Size-exclusion chromatograms for the mutant mouse Pmm2 proteins.
C: Percentage of aggregates and His6PMM2 dimers for each mutant (except for p.F207S due to its lack of solubility in the bacterial extracts, and
p.P113L given the impossibility of obtaining oligomeric fractions). The total amount of purified protein was considered to represent 100% in each
case. D: Western blot of human and mouse pure PMM2/Pmm2 WT and mutant proteins. Equal volumes obtained from the dimer fraction of each
protein were loaded onto the SDS-PAGE gel.
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Figure 2. PMM2 activity. A: His6PMM2 WT and mutant protein activity as determined in bacterial extracts. p.F207S activity could not be
determined since it was not expressed in the bacterial extracts. B: Pure dimeric His6PMM2WT and mutant protein activity. No oligomeric forms of
p.P113L could be obtained; its activity was therefore not determined. WT activity (mU/mg protein) was considered to represent 100%. The results
reflect the average of at least three independent experiments (∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001).
It should be noted that none of the oligomerization patterns
showed a monomer peak, indicating that PMM2 monomers are
likely unstable and tend to aggregate (Fig. 1A).
Some mutants showed a strong tendency to aggregate; for
p.R123Q, p.R141H, and p.C241S, the active dimeric forms rep-
resented less than half of the purified protein (Fig. 1A and C;
Table 1).
Theamountof thep.F118LmousePmm2mutantpurifiedprotein
was 70%of the pureWTprotein, and showed the same oligomeriza-
tion pattern, whereas the behavior of p.R137Hwas similar to that of
its human analogue p.R141H, showing an oligomerization pattern
with an abundance of aggregates (Fig. 1B and C; Table 1).
The purified normal andmutant dimers obtained by gel filtration
were analyzed by western blotting (Fig. 1D). Significant differences
were observed in the amount of purifiedprotein obtained frommost
of the mutants compared with the WT; under the same conditions,
they were generally much lower for all mutants, although p.F118L
mouse Pmm2 production reached some 70% of the WT total
(Table 1).
PMM2 Activity
PMM2 catalytic activity was analyzed using the soluble bacterial
extracts (Fig. 2A) and the pure PMM2 dimer forms of the WT
and mutant proteins (Fig. 2B). Remarkable differences were seen in
the activity of the WT and mutant proteins, with the activity decay
trend similar in both systems. The results obtainedwith the bacterial
extracts showed a lower PMM2 activity in all mutants compared
with the WT one (0.4%–31.5% of the latter’s activity) (Fig. 2A;
Table 1), whereas for the pure dimeric proteins, the residual activity
ranged from 16% for p.V44A to 47% for p.R162W. p.D65Y showed
32%activity comparedwith theWT,whereas p.T237Mand p.C241S
showed 26%–27%. Almost null catalytic activity was recorded for
p.R123Q andp.R141H (Fig. 2B; Table 1). Since p.P113L and p.F207S
could not be purified, their activities were not determined. The
mouse mutant p.F118L retained 10% of the Pmm2 WT activity
recorded for the bacterial extract, and around 15% of that recorded
for the pure dimeric protein. As seen for human PMM2 p.R141H,
p.R137H showed null activity (Fig. 2; Table 1).
PMM2 Stability Analysis
The thermal stability of the PMM2 mutants was examined by
DSF, using the dimeric fraction of the purified proteins (Table 1).
Compared with the WT, all the purified human PMM2 mutants
showed Tm downshifts of between 0.7°C and 10°C, revealing their
intrinsic instability with respect to the WT form. The p.R123Q
mutant protein was the most resistant to thermal denaturation,
its Tm downshifting by only 0.7°C compared with the WT, whereas
p.D65Y,with aTm downshift of 10°C,was themost sensitive (Fig. 3A;
Table 1). The p.F207S and p.P113L mutant proteins could not be
analyzed since no dimeric protein could be obtained. The mouse
Pmm2mutants, p.R137H, showed a downshift of around 4°C com-
pared with the WT Pmm2 curve, similar to its human PMM2 ana-
logue p.R141H. In contrast, p.F118L Pmm2 showed no Tm shift,
suggesting this mutation does not affect the protein’s thermal sta-
bility (Fig. 3B; Table 1).
To further investigate the stability of the mutant proteins, time
course degradation ofWTHis6PMM2 andHis6PMM2mutant pro-
teins were compared in the prokaryotic transduction–translation-
coupled system. PMM2 was immunodetected and the bands quan-
tified by laser densitometry to determine the half-lives (Fig. 4A).
Western blotting detected a low molecular weight band that in-
creased in intensity over almost all degradation time courses, fur-
ther evidencing the unstable nature of the mutations. This band is
likely a PMM2 degradation by-product from the N-terminal region
since it disappeared in the presence of a His antibody (data not
shown).
Human mutant protein half-lives at 37°C were reduced by
20%–60% compared with the WT, confirming all the mutants to
be more unstable than the WT (Fig. 4C; Table 1). The half-life of
p.V44A is not shown since the results obtained were inconsistent
(Fig. 4A and C). The half-life of the mouse mutant p.F118L at 37°C
seemed not to be affected compared with the WT Pmm2 protein
(Fig. 4B and C). This adds weight to the previous results suggest-
ing that mouse mutation p.F118L does not affect protein stability.
It should be noted that the half-life of human PMM2, as deter-
mined by this method, is much shorter than that of mouse Pmm2
(around 30 min for the human protein and 5.4 hr for the mouse
protein).
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Figure 3. Differential scanning fluorimetry. A: DSF results for the human PMM2 mutants. B: DSF results for the mouse Pmm2 mutants.
Representative thermal denaturation profiles for pure mutants (black line) compared with the WT (gray line). The experimental unfolding curves
were smoothed, normalized, and analyzed using in-house software. The lower figure in each graph represents the data without scaling.
Figure 4. Degradation time courses for PMM2 proteins expressed in the prokaryotic set (transcription–translation-coupled assay).A: Represen-
tative western blot of human PMM2WT and mutant proteins incubated at 37°C for 1 hr. The half-life of p.V44A is not shown due to the inconsistent
results obtained. B: Representative western blot of mouse Pmm2 WT and mutant proteins incubated at 37°C for 7 hr. Equal volumes were loaded
onto the SDS-PAGE gel and the protein immunodetected using anti-PMM2 antibodies. Time 0 has been loaded by duplicate. C: Representation
of how mutant protein half-lives decrease compared with the WT (considered to reflect 100%). The results reflect the average of at least three
independent experiments (∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001).
PMM2 Activity and Steady-State Protein Level Under
Permissive Conditions in a Eukaryotic System
PMM2 activity and stability were also studied in a eukary-
otic system. Control- and patient-derived fibroblast lines P1
(p.R141H/p.R162W), P2 (c.640-9T>G/p.T237M), P3 (p.Q33∗/p.
V44A), and P4 (p.R141H/p.D65Y) were transfected with their
own folding mutations—p.R162W p.T237M, p.V44A, and p.D65Y,
respectively—to increase the amount of protein produced. PMM2
activity assays and western blotting were performed on the soluble
part of cell extracts from the patient-derived fibroblast overexpress-
ing the mutants incubated under permissive folding conditions at
28°C. PMM2 levels and activity were recovered to some extent in
all cases (Fig. 5). No increase in activity was seen for the P3 or P4
cells after 45 min at 37°C (unlike for C, P1 and P2); the incubation
time was therefore increased to 4 hr at which time an increase was
observed.
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Figure 5. PMM2 activity and steady-state protein level under permissive folding conditions in the eukaryotic system. A: PMM2 activity in the
soluble part of the cellular extract from patient-derived fibroblasts stably transfected with their own folding mutations and incubated at 37°C
or 28°C. The control PMM2 activity at 37°C was taken as 1. The results reflect the average of at least three independent experiments (∗P <
0.05; ∗∗P < 0.01; ∗∗∗P > 0.001). B: Western blot result for the soluble part of the cellular extract. Cell line genotypes. C: Control overexpressing
the WT Flag-PMM2: P1, p.R141H/p.R162W overexpressing the p.R162W mutant; P2, c.640-9T>G/p.T237M overexpressing the p.T237M mutant; P3,
p.Q33X/p.V44A overexpressing the p.V44A mutant; and P4, p.R141H/p.D65Y overexpressing the p.D65Y mutant.
FoldX Prediction Effect on PMM2 Stability
The computer algorithm FoldX v.3.0 was employed to gain com-
plimentary insight into the effects of PMM2 mutations on protein
stability. This algorithm provides a rapid, quantitative estimation
of the interactions that contribute toward the stability of proteins.
All the mutant proteins, except for p.R162W, seemed to be less
stable than the WT; their differences in free energy ranged from
0.22 to 6.51 Kcal/mol as compared with the WT. p.F207S was the
most unstable mutant. These results correlate with the lack of ex-
pression of p.F207S in the prokaryotic system. p.R162W appeared
to be more stable than the WT, a likely consequence of the in silico
nature of the present method (Table 1). Since no crystallized mouse
Pmm2 protein was available, predictions for p.F118L Pmm2 were
made using its human PMM2 analogue p.F122L. The result showed
a difference in free energy with respect to the WT of 0.81 Kcal/mol
(Table 1), indicating the p.F122L PMM2 mutant to be quite un-
stable. Despite this result, p.F118L Pmm2 instability could not be
proved experimentally.
Discussion
The comprehensive analysis of the mechanisms of action asso-
ciated with a mutation is an essential step in the development of
personalized treatments for patients with a genetic disease. The
analysis of these mechanisms also helps to make predictions regard-
ing disease outcome. In the present work, the mechanisms of action
of several mutations associated with PMM2-CDG were examined.
The present results show that the mutations p.V44A, p.D65Y,
p.R162W, p.R123Q, p.R141H, p.F207S, p.T237M, and p.C241S af-
fect the folding properties of the PMM2 protein, whereas p.P113L
affects the oligomerizationof thePMM2subunits. Structurally, both
mutations p.R123Q and p.R141H also affect the catalytic proper-
ties of the protein [Silvaggi et al., 2006; Vega et al., 2011]. The
results also highlight the possibility of recovering enzyme activity
in the p.V44A, p.D65Y, p.R162W, and p.T237M mutation settings.
Steady-state protein levels were recoverable under permissive fold-
ing conditions (28°C) in the eukaryotic expression system.
The pure protein activity results classify the studied mutants into
two categories: variants with intermediate residual activity rang-
ing from 16.6% to 47.3% (p.V44A, p.D65Y, p.R162W, p.T237M,
and p.C241S) that of WT, and variants with null residual activity
(p.R123Q and p.R141H)—probably mutations affecting the cat-
alytic site, as indicated by their location within the structure of the
protein [Silvaggi et al., 2006; Vega et al., 2011].
Basedon the results,we suggest a possible classificationof thenine
selected mutations as follows: (1) destabilizing mutations (p.V44A,
p.D65Y, p.R162W, p.T237M, p.F207S, and p.C241S) that retain
some residual activity, (2) folding and functional mutations, af-
fecting both folding and catalytic properties of the PMM2 pro-
tein (p.R123Q and p.R141H) that retain null residual activity, and
(3) oligomerizationmutation affecting PMM2protein dimerization
(p.P113L).
The results obtained by expression and purification of the
nine human mutants in the prokaryotic systems, plus the activity
assays and degradation time course experiments, the oligomeric and
thermal stability profiles, the western blot findings, and the steady-
state protein levels studied in the eukaryotic system, suggest that the
loss of function of most of these mutant proteins is based on in-
creased susceptibility to degradation and/or aggregation (compared
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with theWT), a commonmechanism underlying the so-called con-
formational diseases caused by protein reduction due to mutants’
instability [Gregersen et al., 2006; Muntau et al., 2014; Underhaug
et al., 2012].
The degradation of PMM2 proteins harboring missense muta-
tions might be promoted by a folding defect or lie in a problem of
oligomeric assembly; certainly, dimer production seems to be es-
sential for the correct functioning of the protein. This work is the
first to report an oligomeric profile of PMM2mutations along with
thermal stability data that show the effect of these mutations on the
protein’s folding properties.
The destabilizing effect of mutations on the PMM2 protein was
also made manifest by the significant differences observed in the
amount of protein obtained (aggregates/dimers ratio) compared
with the WT in crude extracts and pure protein fractions. No pure
protein could be obtained for the p.P113Lmutation due to its insta-
bility. The protein was lost during the purification process but was
detected in the crude bacterial extracts.
Most of the mutations associated with PMM2-CDG are missense
mutations that cause conformational instability resulting in loss of
function [Vega et al., 2011]; however, the present results suggest
that the administration of compounds that improve PMM2 folding
might provide a treatment. Most PMM2-CDG patients are com-
pound hemizygous with one severe mutation (p.R141H, p.F207S,
p.R123Q) and one milder mutation—mostly destabilizing muta-
tions that retain some enzymatic activity [Perez et al., 2011], such as
p.V44A, p.D65Y, p.R162W, p.T237M, and p.C241S. Given the high
symptomatic threshold of the disease, many patients might benefit
from such folding therapy.
One of the aims of the functionalmutation analysis is to attempt a
genotype–phenotype correlation. The clinical heterogeneity present
in PMM2-CDG patients, along with the practical absence of ho-
mozygosity among the studied patients, hinders a straightforward
genotype–phenotype correlation for this disease. After the analysis
of the reported genotypes carrying the studied mutations, we can
conclude that just destabilizingmutations retaining residual activity
have been detected in homozygosity, such as p.T237M and p.D65Y
[Grunewald et al., 2001; Quelhas et al., 2007; Vega et al., 2011].
Furthermore, among the studied mutants, p.R162W and p.T237M
havebeenassociatedwithmildormoderatephenotypes [Grunewald
et al., 2001; Quelhas et al., 2007), whereas p.V44A and p.D65Y have
been related with more severe phenotypes [Grunewald et al., 2001;
Quelhas et al., 2007; Schollen et al., 2007]. This is in agreement
with the fact that p.R162W and p.T237Mmutations seem to have a
milder effect on the PMM2protein, whereas p.V44A andp.D65Y are
both themost unstable ones. Regarding p.C241Smutation, themost
stable studied mutant is clearly associated with a milder phenotype
[Casado et al., 2012; Giurgea et al., 2005; Grunewald et al., 2001].
Finally, the effect of the p.P113L mutation, originally detected in a
homozygous state [Perez et al., 2011; Vega et al., 2011], is, however,
not so straightforward. Indeed, its severity seems to have been un-
derestimated as the presented results show the severe effect on the
protein.
The possibility of using pharmacological chaperones to treat this
disease encouraged the present study in the murine model. The
disruption of the mouse Pmm2 gene can cause early embryonic
lethality [Thiel et al., 2006]. However, the mutations p.R137H and
p.F118L are not lethal to embryos if dams are fed mannose during
gestation. The effect of these mutations on protein level, catalytic
activity, oligomerization profile, and stability revealed the former to
behave like its human homologue p.R141H, classifying it as a muta-
tion that affects the stability and catalytic properties of the protein.
p.F118L does not affect protein stability, although it does interfere
with its catalytic properties. Unfortunately, this mouse model is
inadequate for testing pharmacological chaperones or proteostasis
regulators since neither mutations cause conformational instability.
In summary, the present results suggest that the destabilizing
changes identified in PMM2 might be overcome via the use of
tailored pharmacological chaperones. We are currently working to
identify such molecules.
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